Ebopiprant

DB16147InvestigationalSmall molecule

Ebopiprant is under investigation in clinical trial NCT03369262 (Poc Study of OBE022 in Threatened Preterm Labour).

Mechanism: Pharmacologically active on Prostaglandin F2-alpha receptor
Curator reviewed
Formula / weight: C₃₀H₃₄FN₃O₅S₂ · 599.74 g/mol (avg)
Code names: OBE-022

Resolves to

Compound

Structure

InChIKeyUUIBKACUTXYSAK-YCVJPRETSA-NSMILESCC(C)[C@H](N)C(=O)OCC[C@H](NC(=O)[C@@H]1SCCN1S(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(F)C=C1

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ebopiprant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.